Capricor Therapeutics, Inc. · NASDAQ:CAPR

Capricor Therapeutics — Q1 2020 Earnings Presentation

6 slides from Capricor Therapeutics's earnings presentation, May 14, 2020

  1. Slide 1: Capricor Q1 Earnings Call and Corporate Update

    Capricor Q1 Earnings Call and Corporate Update May 14, 2020 Earnings Call NASDAQ: CAPR 1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding

  3. Slide 3: Immunomodulatory Effects of CAP-1002

    Immunomodulatory Effects of CAP-1002 CDCs: Cardiosphere-derived cells Macrophages Proinflammatory Systemic Inflammation 1. Cardiac inflammation Cytokines 2. Lung inflammation 3. Cardiomyocyte death Effector T-cells 4. Cardiac dysfunction Multiorgan dysfunction IFN-γ, TNFα, IL-1β, 5. Skeletal muscle

  4. Slide 4: HOPE-2 Top-Line 12-month Data Summary

    HOPE-2 Top-Line 12-month Data Summary  Upper Limb Function:  Full PUL 2.0 – change observed of 2.4 points (p=0.05)  Mid Level PUL 1.2 – change observed of 2.8 points (p=0.08)  Full PUL 1.2 – change observed of 4.1 points (p=0.03)  Cardiac Function:  LV Ejection Fraction (%) – change observed o

  5. Slide 5: Primary Efficacy Endpoint - Performance of the Upper Limb (Mid PUL 1.2)

    Primary Efficacy Endpoint - Performance of the Upper Limb (Mid PUL 1.2) Complete PUL 1.2 data (mid)set Excludes PUL non-responder (n=1) 1.2 (mid) MONTH 12/ET Mean Change from Baseline +/- SEM MONTH 12/ET 5 0 Mean Change from Baseline +/-SEM CAP-1002 0 -1 PLACEBO -2 -5 -3 -4 -10 p=0.0974 -5 (t test;

  6. Slide 6: Performance of the Upper Limb (Full PUL 2.0)

    Performance of the Upper Limb (Full PUL 2.0) Complete PUL data set 2.0 (full) Excludes PUL non-responder (n=1) 2.0 (full) MONTH 12/ET MONTH 12/ET Mean Change from Baseline +/- SEM 4 0 Mean Change from Baseline +/-SEM CAP-1002 2 -1 PLACEBO 0 -2 -2 -3 -4 -4 -6 p=0.0201 (t test; two-tailed) -5 -8 -6 p=

Capricor Therapeutics — Q1 2020 Earnings Presentation on 6ix